A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2002
11/28/2002	WO2002094368A1 Transdermal drug delivery devices having coated microprotrusions
11/28/2002	WO2002094342A2 Compositions for protein delivery via the pulmonary route
11/28/2002	WO2002094314A1 Tsg101 as inhibitor of hiv production
11/28/2002	WO2002094312A1 Polypeptides derived from human telomerase reverse transcriptase
11/28/2002	WO2002094310A1 Anti-angiogenic and immunotherapeutic compositions for cancer treatment
11/28/2002	WO2002094309A1 Composition and methods for affecting metallocorrinoid uptake
11/28/2002	WO2002094308A1 Improved neuronal gene transfer
11/28/2002	WO2002094307A1 Yin yang-1
11/28/2002	WO2002094306A1 Remedies for nervous tumor
11/28/2002	WO2002094305A1 Use of tripeptide gpe for treating or preventing symptoms of parkinson's disease
11/28/2002	WO2002094304A1 The use of a gatran for the manufacture of a medicament for the treatment of pulmonary fibrosis
11/28/2002	WO2002094271A1 Targeted delivery of bioaffecting compounds for the treatment of cancer
11/28/2002	WO2002094256A1 Lysine and/or analogues and/or polymers thereof for promoting wound healing and angiogenesis
11/28/2002	WO2002094250A2 Therapeutic uses of lna-modified oligonucleotides in infectious diseases
11/28/2002	WO2002094204A1 Dental restorative materials
11/28/2002	WO2002094202A2 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
11/28/2002	WO2002094201A2 Composition and method for treating cells
11/28/2002	WO2002094200A2 Pulmonary administration of chemically modified insulin
11/28/2002	WO2002094195A2 Methods and compounds for the diagnosis of inflammatory disease and identification of pharmacological agents
11/28/2002	WO2002094194A2 Compositions and methods for inhibiting metastasis
11/28/2002	WO2002094084A2 Bmpr1a involvement in juvenile polyposis
11/28/2002	WO2002094029A1 Method of inhibiting fungal growth
11/28/2002	WO2002093998A2 Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof
11/28/2002	WO2002083712A8 Transporters and ion channels
11/28/2002	WO2002083176A8 Biomaterials comprising a melanocyte stimulating hormone (msh), and method of forming
11/28/2002	WO2002080858A3 Use of kpv tripeptide for dermatological disorders
11/28/2002	WO2002079408A3 Short bioactive peptides and methods for their use
11/28/2002	WO2002078675A3 Particles for inhalation having sustained release properties
11/28/2002	WO2002077198A3 Methods of modulating angiogenesis
11/28/2002	WO2002077019A9 Methods and compositions for modulating tumor suppression
11/28/2002	WO2002072631A8 Mhc molecule constructs and their usesfor diagnosis and therapy
11/28/2002	WO2002070563A3 Nuclear hormone receptor ligand binding domain
11/28/2002	WO2002068652A9 Nov-x proteins and nucleic acids encoding same
11/28/2002	WO2002066636A3 T cell receptor variants expressed in mesenchymal cells and uses thereof
11/28/2002	WO2002062979A3 Enzyme
11/28/2002	WO2002062289A3 Method for treating respiratory distress syndrome
11/28/2002	WO2002056837A9 Inhibition of protein-phosphatases for the treatment of heart failure
11/28/2002	WO2002050304A3 Oncolytic virus
11/28/2002	WO2002047711A3 Modulators of activity of g-protein-coupled receptor kinases
11/28/2002	WO2002040538A3 Regulation of human nmda receptor
11/28/2002	WO2002036733A3 Cd36 as a heat shock protein receptor and uses thereof
11/28/2002	WO2002035235A3 Net as regulator of angiogenic expression
11/28/2002	WO2002024924A3 Protein phosphatases
11/28/2002	WO2002022791A3 Regulation of human pyridoxine 5'-phosphate oxidase
11/28/2002	WO2002022665A9 Novel g protein-coupled receptor proteins and dnas tehreof
11/28/2002	WO2002022177A3 High efficiency cardiac gene transfer
11/28/2002	WO2002015977A3 Methods and compositions for treating ige-related disease using nnt-1 inhibitors
11/28/2002	WO2002008255A3 Cell cycle proteins and mitosis-associated molecules
11/28/2002	WO2001098360A3 Gp354 nucleic acids and polypeptides
11/28/2002	WO2001096393A9 Nucleotide and amino acid sequences of oocyte factors for altering ovarian follicular growth in vivo or in vitro
11/28/2002	WO2001095919A3 A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
11/28/2002	WO2001090345A3 Methods and compositions for enhancing the delivery of a nucleic acid to a cell
11/28/2002	WO2001085764A3 Regulation of human p2y-like g protein-coupled receptor
11/28/2002	WO2001082897A3 Liposome drug delivery
11/28/2002	WO2001081415A3 Parathyroid hormone and parathyroid hormone-related protein antagonists
11/28/2002	WO2001070954A9 Regulation of human nerve growth factor-elated g protein-coupled receptor
11/28/2002	WO2001026575A9 Methods of diagnosing and treating urinary incontinence
11/28/2002	WO2001018021A9 B7-like polynucleotides, polypeptides, and antibodies
11/28/2002	WO2000050070A9 Preparation for the treatment of pigmentation disorders
11/28/2002	US20020178459 Genetically engineered mammal for use in the treatment of muscle and liver disorders
11/28/2002	US20020178458 Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd534 as a target
11/28/2002	US20020178135 Image searching system and image searching method, and a recording medium storing an image searching program
11/28/2002	US20020177839 Microprojection array having a beneficial agent containing coating
11/28/2002	US20020177725 Peptide inhibitors of hepatitis C virus NS3 protein
11/28/2002	US20020177700 New ras-like protein
11/28/2002	US20020177699 Human phosphatidylinositol synthase
11/28/2002	US20020177696 Compositions and methods relating to breast specific genes and proteins
11/28/2002	US20020177689 Compounds for the treatment of sexual dysfunction
11/28/2002	US20020177688 Genetically engineered polypeptide for use in the treatment of infections, inflammation, hematopietic, bone and wound disorders
11/28/2002	US20020177614 Preventing neural tissue damage caused by adenosine-diphosphate- ribosylation of eucaryotic elongation factor-2 (EF-2)
11/28/2002	US20020177610 Hypolipidemics; treating obesity and disorders of lipid metabolism
11/28/2002	US20020177594 Inhibitors of histone deacetylase
11/28/2002	US20020177571 Retroviral vector particle comprising a modified viral surface protein for targeting the vector (especially to the Von Willebrand factor) and a cytokine gene.
11/28/2002	US20020177568 Enzymatic nucleic acid treatment of diseases or conditions related to levels of NF-kappa B
11/28/2002	US20020177567 Comprising a HER-2/neu extracellular domain fused to a HER-2/neu phosphorylation domain, wherein the protein is capable of producing an immune response in a warm-blooded animal.
11/28/2002	US20020177565 Toso proteins and related molecules which have an inhibitory effect on TNF mediated apoptosis
11/28/2002	US20020177560 Method of preparation of stabilized thrombin-activatable fibrinolysis inhibitor (TAFI) and methods of use thereof
11/28/2002	US20020177557 Peptides and mimetics are based on the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP.
11/28/2002	US20020177556 Especially treating Alzheimer's disease with cetrorelix.
11/28/2002	US20020177555 Precementum- and / or cementum - derived chemotactic factor (CCTF) of tooth of mammalia, process for purifying the same, and drug for accelerating adhesion of new connective tissue, comprising the same as active ingredient
11/28/2002	US20020177554 Novel peptides for use in treatment of T-cell mediated cartilage destruction in autoimmune diseases
11/28/2002	US20020177553 Secreted and transmembrane polypeptides and nucleic acids encoding the same
11/28/2002	US20020177552 Colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions; alternatively, antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a
11/28/2002	US20020177551 Mammalian cell receptor useful in the treatment of cancer which binds tumor associated lipids wherein said binding induces anergy or apoptosis in said T cells and antigen presenting cells.
11/28/2002	US20020177550 Administering to the subject a therapeutically effective amount of a form of soluble Receptor for Advanced Glycation Endproducts (RAGE).
11/28/2002	US20020177549 Which regulate cellular guidance and physiology, and related nucleic acids.
11/28/2002	US20020177546 Treating with a mixture comprising insulin combined with serotonin.
11/28/2002	US20020177545 Compositions and methods for treating gonadotrophin related illnesses
11/28/2002	US20020177544 Adenoviral transfer vector for the gene transport of a dna sequence
11/28/2002	US20020177226 Pharmaceutical dipeptide compositions and methods of use thereof: immunostimulants
11/28/2002	US20020177218 Methods of detecting multiple DNA binding protein and DNA interactions in a sample, and devices, systems and kits for practicing the same
11/28/2002	US20020177215 Methods for producing purified adenoviral vectors
11/28/2002	US20020177213 Tissue plasminogen activator-like protease
11/28/2002	US20020177212 Polypeptide that interacts with heat shock proteins
11/28/2002	US20020177211 Zace2: a human metalloenzyme
11/28/2002	US20020177209 Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy
11/28/2002	US20020177208 Polypeptide for use in the diagnosis, treatment and prevention of cancer and inflammation
11/28/2002	US20020177205 Mammalian alpha-kinase proteins, nucleic acids and diagnostic and therapeutic uses thereof
11/28/2002	US20020177195 Production of human mutated proteins in human cells by means of homologous recombination
11/28/2002	US20020177193 Growth factor homolog zvegf3

1 ... 1948 1949 1950 1951 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 ... 3163